[1] |
Wu H, Jiang S, Zhong P, et al. Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary[J]. J Ovarian Res, 2021, 14(1):137. doi: 10.1186/s13048-021-00896-9.
pmid: 34674727
|
[2] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660.
|
[3] |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J(Engl), 2021, 134(7):783-791. doi: 10.1097/CM9.0000000000001474.
|
[4] |
Hubbard AK, Poynter JN. Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012[J]. Gynecol Oncol, 2019, 154(3):608-615. doi: 10.1016/j.ygyno.2019.06.025.
pmid: 31303255
|
[5] |
Wang T, Wang B, Wang SX, et al. Clinicopathologic Characteristics and Survival of Patients with Rare Malignant Ovarian Yolk Sac Tumors: A Population-based Analysis[J]. Curr Med Sci, 2021, 41(2):342-347. doi: 10.1007/s11596-021-2353-y.
pmid: 33877552
|
[6] |
Saeed Usmani A, Yasin I, Asif RB, et al. Incidence and Survival Rates for Female Malignant Germ Cell Tumors: An Institutional Review[J]. Cureus, 2022, 14(4):e24497. doi: 10.7759/cureus.24497.
|
[7] |
Boyraz G, Durmus Y, Cicin I, et al. Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases[J]. Arch Gynecol Obstet, 2019, 300(1):175-182. doi: 10.1007/s00404-019-05160-6.
pmid: 30982145
|
[8] |
Nasioudis D, Mastroyannis SA, Latif NA, et al. Trends in the surgical management of malignant ovarian germcell tumors[J]. Gynecol Oncol, 2020, 157(1):89-93. doi: 10.1016/j.ygyno.2020.01.033.
pmid: 32008791
|
[9] |
Iscar T, Arean C, Chiva L, et al. Ovarian yolk sac tumor[J]. Int J Gynecol Cancer, 2021, 31(5):797-798. doi: 10.1136/ijgc-2021-002538.
pmid: 33931463
|
[10] |
Ju UC, Kang WD, Kim SM. Enhancing the accuracy of preoperative and intraoperative evaluation of malignant ovarian germ cell tumors with a focus on fertility preservation in young women[J]. Int J Gynaecol Obstet, 2025, 168(3):1238-1243. doi: 10.1002/ijgo.15916.
|
[11] |
Qin L, Wang B, Wang Z, et al. Clinicopathological features, prognosis, and fertility outcomes in Chinese Han women treated for ovarian yolk sac tumor: A retrospective case series study from two tertiary-care academic medical centers[J]. Medicine(Baltimore), 2022, 101(29):e29868. doi: 10.1097/MD.0000000000029868.
|
[12] |
Guo H, Chen H, Wang W, et al. Clinicopathological Features, Prognostic Factors, Survival Trends, and Treatment of Malignant Ovarian Germ Cell Tumors: A SEER Database Analysis[J]. Oncol Res Treat, 2021, 44(4):145-153. doi: 10.1159/000509189.
|
[13] |
Vasta FM, Dellino M, Bergamini A, et al. Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery[J]. Biomedicines, 2020, 8(12):554. doi: 10.3390/biomedicines8120554.
|
[14] |
中华医学会妇科肿瘤学分会, 中国医师协会妇产科医师分会妇科肿瘤学组, 杨佳欣, 等. 卵巢恶性生殖细胞肿瘤临床诊治中国专家共识[J]. 现代妇产科进展, 2024, 33(8):561-568. doi: 10.13283/j.cnki.xdfckjz.2024.08.001.
|
[15] |
Zamani N, Rezaei Poor M, Ghasemian Dizajmehr S, et al. Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences[J]. BMC Womens Health, 2021, 21(1):282. doi: 10.1186/s12905-021-01437-8.
|
[16] |
Turkmen O, Karalok A, Basaran D, et al. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors[J]. J Adolesc Young Adult Oncol, 2017, 6(2):270-276. doi: 10.1089/jayao.2016.0086.
|
[17] |
过华蕾, 陈豪, 王文慧, 等. 保留生育功能手术及淋巴结切除对卵巢恶性生殖细胞肿瘤患者预后的影响:基于SEER数据库的研究[J]. 浙江医学, 2022, 44(20):2154-2159. doi: 10.12056/j.issn.1006-2785.2022.44.20.2022-1149.
|
[18] |
Qin B, Xu W, Li Y. The impact of lymphadenectomy on prognosis and survival of clinically apparent early-stage malignant ovarian germ cell tumors[J]. Jpn J Clin Oncol, 2020, 50(3):282-287. doi: 10.1093/jjco/hyz180.
pmid: 31867612
|
[19] |
Mahdi H, Swensen RE, Hanna R, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary[J]. Br J Cancer, 2011, 105(4):493-497. doi: 10.1038/bjc.2011.267.
|
[20] |
Wang J, Chen R, Li J, et al. The individualized significance of lymphadenectomy across all age groups and histologies in malignant ovarian germ cell tumors[J]. Arch Gynecol Obstet, 2020, 302(6):1441-1450. doi: 10.1007/s00404-020-05772-3.
|
[21] |
陈雪莲, 何连利. 基于SEER数据库分析卵巢卵黄囊瘤的临床病理特征及预后影响因素[J]. 现代妇产科进展, 2022, 31(10):751-757. doi: 10.13283/j.cnki.xdfckjz.2022.10.030.
|
[22] |
Li S, Zhang X, Zhang T, et al. Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors[J]. Gynecol Oncol, 2023, 178:145-152. doi: 10.1016/j.ygyno.2023.10.006.
pmid: 37865050
|